Citations

Showing 10 of 108094 citations.

Point estimation following two‐stage adaptive threshold enrichment clinical trials
Kimani, Peter , Todd, Susan , Renfro, Lindsay A. , Stallard, Nigel , Kimani, Peter K

Mayo Clinic

Statistics in Medicine | June 1, 2018 | Volume: 37 | Issue: 22 | Pages: 3179-3196

10.1002/sim.7831 | PMID 29855066 Get It

Recently, several study designs incorporating treatment effect assessment in biomarker‐based subpopulations have been proposed. Most statistical methodologies for such designs focus on the control of type I error rate and power. In this paper, we have developed point estimators for clinical trials that use the two‐stage adaptive enrichment threshold design. The design consists of two stages, where in stage 1, patients are recruited in the full population. Stage 1 outcome data are then used to perform interim analysis to decide whether the trial continues to stage 2 with the full population or a subpopulation. The subpopulation is defined based on one of the candidate threshold values of a numerical predictive biomarker. To estimate treatment effect in the selected subpopulation, we have derived unbiased estimators, shrinkage estimators, and estimators that estimate bias and subtract it from the naive estimate. We have recommended one of the unbiased estimators. However, since none of the estimators dominated in all simulation scenarios based on both bias and mean squared error, an alternative strategy would be to use a hybrid estimator where the estimator used depends on the subpopulation selected. This would require a simulation study of plausible scenarios before the trial.
Microbiota‐gut‐brain axis: Interaction of gut microbes and their metabolites with host epithelial barriers
Bhattarai, Yogesh , Bhattarai, Y

Mayo Clinic

Neurogastroenterology & Motility | June 1, 2018 | Volume: 30 | Issue: 6 | Pages: No page available

10.1111/nmo.13366 | PMID 29878576 Get It

AbstractThe gastrointestinal barrier and the blood brain barrier represent an important line of defense to protect the underlying structures against harmful external stimuli. These host barriers are composed of epithelial and endothelial cells interconnected by tight junction proteins along with several other supporting structures. Disruption in host barrier structures has therefore been implicated in various diseases of the gastrointestinal tract and the central nervous system. While there are several factors that influence host barrier, recently there is an increasing appreciation of the role of gut microbiota and their metabolites in regulating barrier integrity. In the current issue of Neurogastroenterology and Motility, Marungruang et al. describe the effect of gastrointestinal barrier maturation on gut microbiota and the blood brain barrier adding to the growing evidence of microbiota‐barrier interactions. In this mini‐review I will discuss the effect of gut microbiota on host epithelial barriers and its implications for diseases associated with disrupted gut‐brain axis.
Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE‐HSS)—an important first step. Authors’ reply
Pai, Rish K. , Bredenoord, Albert J. , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, Vipul , Feagan, B G , Jairath, V , Jairath, V , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 31, 2018 | Volume: 47 | Issue: 12 | Pages: 1714-1715

10.1111/apt.14658 | PMID 29878503 Get It

Linked contentThis article is linked to Warners et al and Conner and Kirsch papers. To view these articles https://doi.org/10.1111/apt.14559 and https://doi.org/10.1111/apt.14633.
Proposal for Modification of Cahan's Criteria Utilizing Molecular Genetic Analyses for Cases without Baseline Histopathology: A Unique Method Applicable to Primary Radiosurgery
Rusheen, Aaron E. , Smadbeck, James B. , Schimmenti, Lisa A. , Klee, Eric W. , Link, Michael J. , Vasmatzis, George , Carlson, Matthew L. , Schimmenti, Lisa A

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 31, 2018 | Volume: 80 | Issue: 01 | Pages: 010-017

10.1055/s-0038-1655759 | PMID 30733895 Get It

Background Cahan's criteria have been utilized since 1948 to establish causality between prior radiation treatment and the development of secondary malignancy. One major criterion specifies that histological and radiographic evidence collected before and after radiation treatment must confirm separate tumor types; however, pretreatment biopsy is rarely obtained prior to radiosurgery for vestibular schwannoma and many other skull base and cranial lesions. Therefore, in these cases Cahan's criteria cannot be validly applied. Objective This article proposes an update to Cahan's criteria using modern molecular genetic analysis for cases lacking baseline histopathology. Methods Mate-pair sequencing and whole exome sequencing of a cerebellopontine angle undifferentiated high-grade pleomorphic sarcoma (UHGPS) that developed after stereotactic radiosurgery of a presumed benign vestibular schwannoma. Results Mate-pair sequencing and whole exome sequencing of the sarcoma revealed complex chromosomal aberrations. Notably, the tumor contained a deletion in the NF2 gene at 22q12 and an in-frame deletion on exon 5 of the remaining copy of NF2. Biallelic events impacting NF2 are atypical for UHGPS but are characteristic for vestibular schwannoma. These findings help support the conclusion that the UHGPS arose from a benign vestibular schwannoma all along. Conclusions Next-generation sequencing can be successfully applied to a radiation-induced sarcoma when both the original and malignant tumors harbor separate signature genetic markers. As our understanding of the genetic profile of various tumors expand, we believe that next-generation sequencing and other genomic tools will play an increasingly important role in establishing causality between radiation and the development of secondary malignancy.
A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
Depré, Christophe, Antalik, Lubomir, Starling, Amaal J. , Koren, Michael J. , Eisele, Osa , Lenz, Robert , Mikol, Daniel D., Starling, Amaal

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 31, 2018 | Volume: 58 | Issue: 5 | Pages: 715-723

10.1111/head.13316 | PMID 29878340 Get It

Objective To determine the potential impact of erenumab, a human anti‐calcitonin gene‐related peptide (CGRP) receptor monoclonal antibody, on total exercise time (TET), time to exercise‐induced angina, and ST depression in a double‐blind, placebo‐controlled study in patients with stable angina due to documented coronary artery disease. Background The relative importance of the CGRP receptor pathway during myocardial ischemia has not been established. Methods An exercise treadmill test was conducted following a single IV infusion of erenumab 140 mg or placebo. The primary endpoint was the change from baseline in exercise duration as measured by TET with a noninferiority margin of −90 seconds. Safety follow‐up visits occurred through week 12. Eighty‐eight participants were included in the analysis. Results LS mean (SE) change in TET was −2.9 [14.8] seconds in the erenumab group and 8.1 [14.4] seconds in placebo; adjusted mean (90% CI) treatment difference was −11.0 (–44.9, 22.9) seconds. The CI lower bound (–44.9 sec) did not reach pre‐defined non‐inferiority margin of −90 seconds, demonstrating that TET change from baseline in the erenumab group was non‐inferior to placebo. There was no difference in time to exercise‐induced angina in erenumab and placebo groups (median [90% CI] time of 500 [420, 540] vs 508 [405, 572] seconds; hazard ratio [90% CI]: 1.11 [0.73, 1.69], P = .69) or time to onset of ≥1 mm ST‐segment depression (median [90% CI] time of 407 [380, 443] vs 420 [409,480] seconds; hazard ratio [95% CI]: 1.14 [0.76, 1.69], P = .59). Adverse events were reported by 27% and 32% of patients in erenumab and placebo groups. Conclusions Erenumab did not adversely affect exercise time in a high cardiovascular risk population of patients, supporting that inhibition of the canonical CGRP receptor does not worsen myocardial ischemia.
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | May 31, 2018 | Volume: 93 | Issue: 6 | Pages: 824-840

10.1002/ajh.25104 | PMID 29878489 Get It

Disease overviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (∼15%‐20% over 3‐5 years).DiagnosisDiagnosis is based on the presence of sustained (>3 months) peripheral blood monocytosis (≥1 × 109/L; monocytes ≥10%), along with bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ∼ 30% of patients, while >90% have gene mutations. Mutations involving TET2 (∼60%), SRSF2 (∼50%), ASXL1 (∼40%) and the oncogenic RAS pathway (∼30%) are frequent; while the presence of ASXL1 and DNMT3A mutations and the absence of TET2 mutations negatively impact over‐all survival.Risk stratificationMolecularly integrated prognostic models include; the Groupe Français des Myélodysplasies (GFM), Mayo Molecular Model (MMM), and the CMML specific prognostic model (CPSS‐Mol). Risk factors incorporated into the MMM include presence of nonsense or frameshift ASXL1 mutations, absolute monocyte count > 10 × 109/L, hemoglobin <10 gm/dL, platelet count <100 × 109/L and the presence of circulating immature myeloid cells. The MMM stratifies CMML patients into 4 groups; high (≥3 risk factors), intermediate‐2 (2 risk factors), intermediate‐1 (1 risk factor), and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively.Risk‐adapted therapyHypomethylating agents such as 5‐azacitidine and decitabine are commonly used, with overall response rates of ∼30%‐40% and complete remission rates of ∼7%‐17%; with no impact on mutational allele burdens. Allogeneic stem cell transplant is the only potentially curative option, but is associated with significant morbidity and mortality.
Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine
Bernert, John T., Benowitz, Neal L. , Feng, June, Jacob, Peyton , McGahee, Ernest, Caudill, Samuel P., Scherer, Gerhard , Scherer, Max , Pluym, Nikola , Doig, Mira, Newland, Kirk, Murphy, Sharon E. , Caron, Nicolas , Sander, Lane C. , Shimizu, Makiko , Kim, Sung Hoon , Langman, Loralie J., Pritchett, Jeanita S., Sniegoski, Lorna T., Pirkle, James L. , Wang, Lanqing , Feng, Jun , Yamazaki, Hiroshi , Li, Yao , Blount, Benjamin C.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 31, 2018 | Volume: 27 | Issue: 9 | Pages: 1083-1090

10.1158/1055-9965.epi-17-1127 | PMID 29853481 Get It

AbstractBackground: Biomarkers of tobacco exposure have a central role in studies of tobacco use and nicotine intake. The most significant exposure markers are nicotine itself and its metabolites in urine. Therefore, it is important to evaluate the performance of laboratories conducting these biomarker measurements.Methods: This report presents the results from a method performance study involving 11 laboratories from 6 countries that are currently active in this area. Each laboratory assayed blind replicates of seven human urine pools at various concentrations on three separate days. The samples included five pools blended from smoker and nonsmoker urine sources, and two additional blank urine samples fortified with pure nicotine, cotinine, and hydroxycotinine standards. All laboratories used their own methods, and all were based on some form of liquid chromatography/tandem mass spectrometry.Results: Overall, good agreement was found among the laboratories in this study. Intralaboratory precision was good, and in the fortified pools, the mean bias observed was &lt; + 3.5% for nicotine, approximately 1.2% for hydroxycotinine, and less than 1% for cotinine (1 outlier excluded in each case). Both indirect and direct methods for analyzing the glucuronides gave comparable results.Conclusions: This evaluation indicates that the experienced laboratories participating in this study can produce reliable and comparable human urinary nicotine metabolic profiles in samples from people with significant recent exposure to nicotine.Impact: This work supports the reliability and agreement of an international group of established laboratories measuring nicotine and its metabolites in urine in support of nicotine exposure studies. Cancer Epidemiol Biomarkers Prev; 27(9); 1083–90. ©2018 AACR.
Toward An Integrated Medical Model
Kokmen, Emre

Mayo Clinic

Health Affairs | May 31, 2018 | Volume: 8 | Issue: 2 | Pages: 191-191

10.1377/hlthaff.8.2.191 Get It

What makes a chronic pelvic pain patient satisfied?
Wygant, Jenna N., McGuire, Lois, Bush, Nicole M., Burnett, Tatnai L. , Green, Isabel C. , McGuire, Lois J, Breitkopf, Daniel M.

Mayo Clinic

Journal of Psychosomatic Obstetrics & Gynecology | May 31, 2018 | Volume: 40 | Issue: 3 | Pages: 239-242

10.1080/0167482x.2018.1476486 | PMID 29848157 Get It

Direct Detection and Identification of Prosthetic Joint Infection Pathogens in Synovial Fluid by Metagenomic Shotgun Sequencing
Ivy, Morgan I. , Thoendel, Matthew , Jeraldo, Patricio , Greenwood‐Quaintance, Kerryl E. , Hanssen, Arlen D. , Yao, Janet , Tande, Aaron J. , Mandrekar, Jayawant N. , Patel, Robin , Thoendel, Matthew J, Jeraldo, Patricio R , Chia, Nicholas , Yao, Janet Z, Patel, Robin , Tande, Aaron , Abdel, Matthew P. , Chia, Nicholas , Thoendel, Matthew J

Mayo Clinic

Journal of Clinical Microbiology | May 31, 2018 | Volume: 56 | Issue: 9 | Pages: No page available

10.1128/jcm.00402-18 | PMID 29848568 Get It

Metagenomic shotgun sequencing has the potential to transform how serious infections are diagnosed by offering universal, culture-free pathogen detection. This may be especially advantageous for microbial diagnosis of prosthetic joint infection (PJI) by synovial fluid analysis since synovial fluid cultures are not universally positive and since synovial fluid is easily obtained preoperatively.